ABSORB Post-Approval Clinical Study

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2021

Conditions
Ischemic Heart Disease
Interventions
DEVICE

Absorb BVS

"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."

Trial Locations (5)

32308

Tallahassee Memorial Hospital, Tallahassee

37934

Turkey Creek Medical Center, Knoxville

40207

Baptist Health Louisville, Louisville

46237

Franciscan St. Francis Health, Indianapolis

07631

Englewood Hospital and Medical Center, Englewood

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY

NCT02943616 - ABSORB Post-Approval Clinical Study | Biotech Hunter | Biotech Hunter